Director Emil Kuriakose of MacroGenics Inc filed a Form 4 on November 3, 2026, disclosing the acquisition of stock options and restricted stock units granted on October 30, 2026.

Key Highlights

  • Stock option grant: Kuriakose acquired a stock option (right to buy) covering 44,000 shares of common stock at an exercise price of $2.4, granted October 30, 2026, expiring October 30, 2036.
  • RSU grant: Kuriakose also acquired 7,500 restricted stock units, each representing a contingent right to receive one share of common stock, at a price of $0.
  • Vesting schedule - options: The option vests in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant.
  • Vesting schedule - RSUs: RSUs vest as to 33% of total shares one year after the date of grant and 33% each year thereafter.
  • Post-transaction holdings: Following the reported transactions, Kuriakose directly holds 44,000 derivative securities (options) and 7,500 RSUs.
  • Relationship to issuer: Kuriakose is identified as a Director of MacroGenics Inc (NASDAQ:MGNX).

MacroGenics Director Emil Kuriakose's October 2026 Equity Grant Details

According to the Form 4 filed with the SEC on November 3, 2026, Emil Kuriakose, a Director of MacroGenics Inc (NASDAQ:MGNX), received two equity awards on October 30, 2026. The first is a stock option granting the right to buy 44,000 shares of common stock at an exercise price of $2.4 per share. The option carries a ten-year term, expiring October 30, 2036, and vests in monthly, cumulative 1/36th increments beginning one month from the grant date, as explained in the filing's footnotes.

The second award consists of 7,500 restricted stock units, each of which the filing describes as "a contingent right to receive one share of the Issuer's common stock." These RSUs were acquired at a price of $0 and will vest as to 33% of the total shares one year after the date of grant, with an additional 33% vesting each year thereafter. Both awards are held directly by Kuriakose, according to the filing.

Following the reported transactions, Kuriakose's beneficial ownership stands at 44,000 options and 7,500 RSUs, all held in direct form. The Form 4 was signed by Beth A. Smith as attorney-in-fact on November 3, 2026, and no Table I non-derivative transactions were reported in this filing.

What Was Disclosed

MacroGenics Director Emil Kuriakose disclosed the receipt of a stock option covering 44,000 shares at $2.4 and 7,500 RSUs on October 30, 2026, both subject to multi-year vesting schedules, in a Form 4 filed November 3, 2026.